European journal of preventive cardiology最新文献_第10页

Human intravenous immunoglobulins for recurrent pericarditis: a multicentre cohort study. 人静脉注射免疫球蛋白治疗复发性心包炎：一项多中心队列研究。

IF 8.4 2区医学

European journal of preventive cardiology Pub Date : 2025-04-28 DOI: 10.1093/eurjpc/zwaf250

Valentino Collini, Francesco Venturelli, Razvan Berghi, Alessandro Andreis, Marzia De Biasio, Marco Merlo, Antonio Brucato, George Lazaros, Gianfranco Sinagra, Massimo Imazio

{"title":"Human intravenous immunoglobulins for recurrent pericarditis: a multicentre cohort study.","authors":"Valentino Collini, Francesco Venturelli, Razvan Berghi, Alessandro Andreis, Marzia De Biasio, Marco Merlo, Antonio Brucato, George Lazaros, Gianfranco Sinagra, Massimo Imazio","doi":"10.1093/eurjpc/zwaf250","DOIUrl":"10.1093/eurjpc/zwaf250","url":null,"abstract":"Aims: Based on limited data, intravenous immunoglobulins (IVIG) have been proposed as possible last therapeutic option for recurrent pericarditis (RP). The aim of this multicentre registry was to evaluate the efficacy and safety of IVIG in these patients after failure of other medical therapies.Methods: This multicentre cohort study enrolled consecutive patients with RP treated with IVIG. The primary outcome was the pericarditis recurrence rate after treatment with IVIG.Results: A total of 43 patients (median age 41.7±14.4 years, 65.1% women) were included. The median duration of disease was 39 months (19-70) and the mean recurrences before IVIG was 5 (4-6). Most patients had elevated C-reactive protein (76.7%), pericardial effusion (72.1%) and fever (69.8%). IVIG were administered at a dose of 400-500 mg/kg/day for 5 consecutive days with repeated cycles, if needed. At discharge 40 (93%) patients had achieved clinical remission with IVIG. After a mean follow-up of 73 (20-84) months the number of recurrences and of emergency department admissions/year were reduced respectively from 1.80 to 0.46 and 0.79 to 0.16 events/year (p<0.001). The need for corticosteroid and anakinra use was also reduced significantly by IVIG (respectively from 72.1% to 19.4%; P < 0.001 and 60.5% to 23.3%; P < 0.02). No difference in baseline characteristics was found between the patients who experienced a recurrence after the IVIG treatment and those who did not. No serious adverse events occurred, only one patient discontinued IVIG due to onset of moderate neutropenia, reversible within a few days.Conclusion: In patients with RP refractory to the conventional therapy, IVIG were efficacious and safe in reducing further recurrences after failure of other conventional medical therapies.","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Underestimation of Cardiovascular Risk by the SCORE2 Model in Primary Care: A Call for Recalibration. 初级保健中SCORE2模型对心血管风险的低估：需要重新校准。

IF 8.4 2区医学

European journal of preventive cardiology Pub Date : 2025-04-27 DOI: 10.1093/eurjpc/zwaf253

V M I Voorbrood, A M Bohnen, A P Bosman, P R Rijnbeek, D Rizopoulos, P J E Bindels

{"title":"Underestimation of Cardiovascular Risk by the SCORE2 Model in Primary Care: A Call for Recalibration.","authors":"V M I Voorbrood, A M Bohnen, A P Bosman, P R Rijnbeek, D Rizopoulos, P J E Bindels","doi":"10.1093/eurjpc/zwaf253","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf253","url":null,"abstract":"Background: The SCORE2 model is a derived risk prediction model that estimates the CVE risk. Originally developed with population-based cohort data, this model is also intended to be used in routine primary care to calculate the risk of first-onset CVE and guide treatment decisions.Aim: In this study, we followed adult patients in the Netherlands who visited their general practitioner (GP) and underwent a CVE risk assessment at their GP office. The aim was to relate the results of the SCORE2 model to the observed risk of a first CVE during follow-up.Methods: A retrospective cohort study was conducted of 205,548 patients, analyzing factors including age, sex, smoking status, diabetes, total and HDL cholesterol, and mean systolic blood pressure. The performance of the SCORE2 model was assessed using observed-to-expected (O/E) risk ratios, calibration plots, and C-statistics. Analyses were stratified by sex, age groups (< 50 and ≥ 50 years), and low and moderate risk country categories.Main results: Results indicated a mean observed 10-year risk of 10.1%, notably higher than the model-predicted risk of 6.2%. The O/E ratio in females and men was 1.54 and 1.68 respectively.The mean observed 10-year CVE was in the age groups < 50 years and ≥ 50 years 6.9% and 11%, respectively. (O/E ratio: 1.78 vs. 1.62).Consequently, approximately 35% of patients potentially missed preventive treatments due to SCORE2's underestimation.Conclusion: These findings suggest the SCORE2 model may underestimate CVE risk in primary care, highlighting the need for calibration in this setting.","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Life's Essential 8 and progression of cardiometabolic multimorbidity trajectory: a prospective study of UK Biobank. 生命的本质8和心脏代谢多病轨迹的进展：英国生物银行的前瞻性研究。

IF 8.4 2区医学

European journal of preventive cardiology Pub Date : 2025-04-26 DOI: 10.1093/eurjpc/zwaf247

Miao Huang, Ru Fu, Xiexiong Zhao, Tao Liu, Xiaogang Li, Weihong Jiang

{"title":"Life's Essential 8 and progression of cardiometabolic multimorbidity trajectory: a prospective study of UK Biobank.","authors":"Miao Huang, Ru Fu, Xiexiong Zhao, Tao Liu, Xiaogang Li, Weihong Jiang","doi":"10.1093/eurjpc/zwaf247","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf247","url":null,"abstract":"Aims: To evaluate the impact of Life's Essential 8 (LE8) on the onset and progression trajectory of cardiometabolic multimorbidity (CMM).Methods and results: This prospective study included 240,346 participants (median age, 57 years) free of CMDs at baseline from the UK Biobank. LE8 scores were divided into low, moderate, and high cardiovascular health (CVH) groups at baseline, with higher LE8 scores representing better CVH. CMM was defined as the coexistence of two or three cardiometabolic diseases, including type 2 diabetes (T2D), ischemic heart disease, and stroke. Multi-state model was applied to explore the role of LE8 level in each transition stage of CMM trajectory. During a median follow-up of 14.01 years, 29,551 participants developed first cardiometabolic disease (FCMD), 3,183 developed CMM, and 15,763 died. LE8 scores were significantly associated with an increased risk of transition from health to FCMD or to death, with adjusted HRs (CIs) for high CVH levels of 0.22 (0.20-0.23) and 0.23 (0.21-0.25), respectively. Similar associations were observed in the transitions from FCMD to CMM (HRs: 0.41; 95% CIs: 0.34-0.50) and from FCMD to death (HRs: 0.82; 95% CIs: 0.68-0.98). CVH levels had an impact on disease-specific transitions except from stroke and T2D to death and from CMM to death.Conclusions: This study revealed that LE8 may influence the progression of CMM trajectory. Our results highlight that managing behavior and health factors of LE8 is an important way to mitigate the progression of CMM trajectory.","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical impact of circulating calciprotein particles in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. 循环钙蛋白颗粒对退行性主动脉瓣狭窄经导管主动脉瓣植入术患者的临床影响。

IF 8.4 2区医学

European journal of preventive cardiology Pub Date : 2025-04-26 DOI: 10.1093/eurjpc/zwaf251

Fumiya Anzai, Daisuke Isomatsu, Tomofumi Misaka, Yutaro Sato, Yuuki Muto, Yu Sato, Akihiko Sato, Tetsuro Yokokawa, Takeshi Shimizu, Masayoshi Oikawa, Atsushi Kobayashi, Akiomi Yoshihisa, Yasuchika Takeishi

引用次数: 0

Global, regional, and national perspectives on aortic aneurysm burden from 1992 to 2021: temporal patterns and age-period-cohort analyses. 1992年至2021年全球、地区和国家主动脉瘤负担的视角：时间模式和年龄期队列分析

IF 8.4 2区医学

European journal of preventive cardiology Pub Date : 2025-04-25 DOI: 10.1093/eurjpc/zwaf266

Jian Tang, Xue-Er Cheng, Yi-Sheng He, Man Ge, Qian-Qian Shi, Xiao-Xiao Li, Hai-Fen Wei, Yan-Yu Zhu, Hai-Feng Pan, Peng Wang

{"title":"Global, regional, and national perspectives on aortic aneurysm burden from 1992 to 2021: temporal patterns and age-period-cohort analyses.","authors":"Jian Tang, Xue-Er Cheng, Yi-Sheng He, Man Ge, Qian-Qian Shi, Xiao-Xiao Li, Hai-Fen Wei, Yan-Yu Zhu, Hai-Feng Pan, Peng Wang","doi":"10.1093/eurjpc/zwaf266","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf266","url":null,"abstract":"Aims: To assess the global, regional, and country-specific trends in the burden of Aortic aneurysm (AA) from 1992 to 2021, with a focus on mortality rates, disability-adjusted life years (DALYs), and sociodemographic inequalities.Methods: The Global Burden of Disease (GBD) 2021 study data were utilized to calculate the age-standardized mortality rates (ASMR) and disability-adjusted life year rates (ASDR) for AA in 204 countries. Temporal patterns were assessed using Joinpoint regression and age-period-cohort modeling. Cross-country inequalities were evaluated using the Slope Index of Inequality (SII) and Concentration Index.Results: Globally, the disease burden of AA showed a downward trend. The ASMR for AA decreased from 2.57 per 100,000 (95% UI: 2.37, 2.72) in 1992 to 1.86 per 100,000 (95% UI: 1.67, 2.00) in 2021 (EAPC: -1.36%). The age effect indicated that the age-specific mortality rate sharply escalates with age, but opposite trends exist in period and cohort effects. The gender-specific analysis confirmed a consistently higher burden in males, with more pronounced reductions in high Socio-demographic Index (SDI) regions. Cross-country analyses highlighted widening absolute inequalities (SII: 74.4 to 84.1) but reduced relative inequalities (Concentration Index: 0.48 to 0.28) over time.Conclusion: There is a downward trend in the global burden of AA from 1992 to 2021, with significant disparities observed across genders, age groups, and SDI regions. These findings emphasize the need for prevention through base healthcare services, risk factor management, and equitable access to interventions to effectively address the disproportionate AA burden.","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Raising Awareness of Ischemic Heart Disease in Brazil - A Call to Action. 提高对巴西缺血性心脏病的认识——呼吁采取行动。

IF 8.4 2区医学

European journal of preventive cardiology Pub Date : 2025-04-25 DOI: 10.1093/eurjpc/zwaf262

Adnaldo da Silveira Maia

引用次数: 0

Childhood risk trajectories into adulthood: Fit for future? 童年到成年的风险轨迹：适合未来吗？

IF 8.4 2区医学

European journal of preventive cardiology Pub Date : 2025-04-25 DOI: 10.1093/eurjpc/zwaf249

Henner Hanssen, Christoph Hauser

引用次数: 0

Adherence to lipid lowering therapy in primary prevention - Talk with the patient, again and again. 在一级预防中坚持降脂治疗-与患者反复交谈。

IF 8.4 2区医学

European journal of preventive cardiology Pub Date : 2025-04-25 DOI: 10.1093/eurjpc/zwaf260

Gisle Langslet

引用次数: 0

Childhood HDL-C and Adult ASCVD: Mechanistic Insights and Preventive Implications. 儿童HDL-C和成人ASCVD：机制见解和预防意义。

IF 8.4 2区医学

European journal of preventive cardiology Pub Date : 2025-04-25 DOI: 10.1093/eurjpc/zwaf265

Fariba Ahmadizar, Pradeep Natarajan, Kaavya Paruchuri

引用次数: 0

Cardiovascular disease and dementia - from association to causality? 心血管疾病和痴呆——从关联到因果关系？

IF 8.4 2区医学

European journal of preventive cardiology Pub Date : 2025-04-25 DOI: 10.1093/eurjpc/zwaf264

Kevin K W Olesen, Michael Maeng

引用次数: 0